21st Century pharmaceutical collaboration: The value convergence

Key findings for biopharma convergence

• Purchaser groups are linking administrative claims data with electronic health records to conduct population research – with biopharma collaborators – to better understand important population segments, like patients with more than one chronic disease.
• Healthcare providers, pushed by new payment incentives, are collaborating with the drug industry to measure the effectiveness of therapies on the patients they treat. Prescribing practices increasingly reflect sophisticated cost/benefit analyses.
• New entrants are bringing biosensor technology and digital tools to healthcare to help biopharmaceutical companies better understand the lives of patients, and how they change in response to drug intervention.
• Patient advocacy organizations are creating disease-specific registries for research, and consulting with industry players on clinical trial design and protocols.
• Proposed legislation such as the 21st Century Cures bill would make it easier for drug companies to promote cost effectiveness data as an additional product attribute.